178 related articles for article (PubMed ID: 12823159)
21. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2003 Jan; 17(2):235-41. PubMed ID: 12534408
[TBL] [Abstract][Full Text] [Related]
22. Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.
Tutuian R; Katz PO; Ahmed F; Korn S; Castell DO
Aliment Pharmacol Ther; 2002 Mar; 16(3):473-7. PubMed ID: 11876700
[TBL] [Abstract][Full Text] [Related]
23. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
[TBL] [Abstract][Full Text] [Related]
24. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
[TBL] [Abstract][Full Text] [Related]
25. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
26. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.
Hatlebakk JG; Berstad A
Scand J Gastroenterol; 1996 Oct; 31(10):954-8. PubMed ID: 8898414
[TBL] [Abstract][Full Text] [Related]
27. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
29. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
30. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
31. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
[TBL] [Abstract][Full Text] [Related]
32. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Gardner JD; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Wong WM; Lai KC; Hui WM; Lam KF; Huang JQ; Hu WH; Wong NY; Lam CL; Xia HH; Chan AO; Lam SK; Wong BC
Aliment Pharmacol Ther; 2004 Feb; 19(4):455-62. PubMed ID: 14871286
[TBL] [Abstract][Full Text] [Related]
34. Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms.
Salvatore S; Hauser B; Salvatoni A; Vandenplas Y
Acta Paediatr; 2006 Feb; 95(2):176-81. PubMed ID: 16449023
[TBL] [Abstract][Full Text] [Related]
35. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
36. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH.
Khoury RM; Katz PO; Hammod R; Castell DO
Aliment Pharmacol Ther; 1999 May; 13(5):675-8. PubMed ID: 10233192
[TBL] [Abstract][Full Text] [Related]
37. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Gardner JD; Sloan S; Miner PB; Robinson M
Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
[TBL] [Abstract][Full Text] [Related]
39. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
Gardner JD; Rodriguez-Stanley S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2002 Oct; 16(10):1819-29. PubMed ID: 12269977
[TBL] [Abstract][Full Text] [Related]
40. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.
Inauen W; Emde C; Weber B; Armstrong D; Bettschen HU; Huber T; Scheurer U; Blum AL; Halter F; Merki HS
Gut; 1993 Aug; 34(8):1025-31. PubMed ID: 8174947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
